OTCMKTS:SNPHY Santen Pharmaceutical (SNPHY) Stock Price, News & Analysis → Thousands of investors use this no cost solution | Do you? (From Insider Financial) (Ad) Free SNPHY Stock Alerts $9.68 +0.04 (+0.41%) (As of 04/24/2024 ET) Add Compare Share Share Today's Range$9.68▼$9.7150-Day Range$9.12▼$10.8052-Week Range$7.97▼$10.80Volume527 shsAverage Volume5,684 shsMarket CapitalizationN/AP/E Ratio0.09Dividend Yield498.95%Price TargetN/A Stock AnalysisStock AnalysisChartFinancialsSEC FilingsShort InterestStock AnalysisChartFinancialsSEC FilingsShort Interest Get Santen Pharmaceutical alerts: Email Address Santen Pharmaceutical MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestBearishDividend StrengthWeakBased on Four FactorsSustainabilityN/ANews Sentiment0.00Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.14 out of 5 stars N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Santen Pharmaceutical. Previous Next 2.0 Short Interest Percentage of Shares ShortedShort Interest Ratio / Days to CoverSanten Pharmaceutical has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous month Previous Next 1.7 Dividend Strength Dividend YieldSanten Pharmaceutical pays a meaningful dividend of 1.47%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthSanten Pharmaceutical does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Santen Pharmaceutical is 46.34%. This payout ratio is at a healthy, sustainable level, below 75%. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SNPHY. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 2 news articles for Santen Pharmaceutical this week, compared to 0 articles on an average week. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Santen Pharmaceutical insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 0.05% of the stock of Santen Pharmaceutical is held by institutions. Previous Next 1.3 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Santen Pharmaceutical is 0.09, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 138.29.Price to Earnings Ratio vs. SectorThe P/E ratio of Santen Pharmaceutical is 0.09, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 191.01. Previous Next See Top Rated MarketRank™ Stocks Here Ad TradeSmithThe A.I. story nobody is telling you (Read ASAP)There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...Click here to see Louis' new video for yourself. About Santen PharmaceuticalSanten Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and marketing of pharmaceuticals and medical devices in Japan and internationally. Its product portfolio includes tafluprost/timolol maleate, a prostaglandin F2a derivative and a beta-adrenergic receptor blocker; and netarsudil mesilate and latanoprost, a prostaglandin F2a derivative which is marketing approval phase for the treatment of glaucoma and ocular hypertension. The company also offers sepetaprost, a prostaglandin analogue eye drop drug that is in phase 3 of clinical trials; and latanoprost, an ophthalmic emulsion of a prostaglandin F2a derivative which is filed for marketing approval for the treatment of glaucoma and ocular hypertension. In addition, it provides cyclosporin, an ophthalmic emulsion for the treatment of vernal keratoconjunctivitis; and diquafosol sodium for dry eye treatment. Further, the company develops olodaterol hydrochloride, a ß2 receptor agonist that is in phase 1/2a for the treatment of A dry eye treatment dry eye; sirolimus, an ophthalmic suspension which is in phase 2a for the treatment of 4 Fuchs endothelial corneal dystrophy and meibomian gland dysfunction; epinastine hydrochloride, a histamine H1 receptor antagonist filed for marketing approval for the treatment of allergic conjunctivitis; atropine sulfate, a non-selective muscarinic antagonist that is in phase 2/3 clinical trials for myopia treatment; and AFDX0250BS, an selective muscarinic M2 antagonist which is in phase 2a for the treatment of myopia. Additionally, it offers ursodeoxycholic acid that is in phase 2a of clinical trial for the treatment of presbyopia; and oxymetazoline hydrochloride, a direct-acting alpha adrenergic receptor agonist which is in phase 3 for treatment of ptosis. The company was founded in 1890 and is headquartered in Osaka, Japan.Read More SNPHY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SNPHY Stock News HeadlinesApril 23, 2024 | morningstar.comSanten Pharmaceutical Co LtdApril 20, 2024 | wsj.comSanten Pharmaceutical Co. Ltd. ADRApril 25, 2024 | Schaeffer’s Research (Ad)Just Released: Insider's Secret to Trading OptionsThis Surprisingly Simple Formula Can Double Your Money Collecting Consistent Profits From The Stock Market Is More Accessible Than You Think A small group of individuals are using a legitimate yet rarely discussed strategy to generate income from the stock market. They're NOT day traders. And they're NOT Wall Street suits either. I'm talking about normal "working stiffs" and retirees generating steady income from a source that 99% of investors completely overlook. This overlooked income source can be yours today.December 27, 2023 | finance.yahoo.comSanten Pharmaceutical Co. Ltd. (JP3336000009.SG)October 4, 2023 | msn.comSanten Pharmaceutical Co. - ADR (SNPHY) Price Target Increased by 7.52% to 10.41August 9, 2023 | seekingalpha.comSNPHY Santen Pharmaceutical Co., Ltd.August 4, 2023 | msn.comSanten Pharmaceutical Co., Ltd. reports Q1 resultsJuly 19, 2023 | benzinga.comHarrow Acquires Santen's Branded Ophthalmic PortfolioApril 25, 2024 | Schaeffer’s Research (Ad)Just Released: Insider's Secret to Trading OptionsThis Surprisingly Simple Formula Can Double Your Money Collecting Consistent Profits From The Stock Market Is More Accessible Than You Think A small group of individuals are using a legitimate yet rarely discussed strategy to generate income from the stock market. They're NOT day traders. And they're NOT Wall Street suits either. I'm talking about normal "working stiffs" and retirees generating steady income from a source that 99% of investors completely overlook. This overlooked income source can be yours today.July 19, 2023 | businesswire.comSanten Agrees to Licensing Agreements and Asset Transfer for its Pharmaceutical Products in North AmericaMay 11, 2023 | msn.comSanten Pharmaceutical Co. reports FY resultsAugust 4, 2022 | markets.businessinsider.comSanten Pharmaceutical is about to announce its earnings — here's what to expectJuly 23, 2022 | marketwatch.comOphthalmology Equipment Market Demand Analysis & Opportunity Outlook 2029May 24, 2022 | marketwatch.comOphthalmology Equipment Market Demand, Opportunity, Outlook, Trends, Revenue, Future Growth Opportunities By2029December 2, 2021 | investing.comSanten Pharmaceutical Co (SNPHY)November 11, 2021 | seekingalpha.comSanten Pharmaceutical Co., Ltd. 2021 Q2 - Results - Earnings Call PresentationSee More Headlines Receive SNPHY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Santen Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Drug Manufacturers - General Sub-IndustryN/A Current SymbolOTCMKTS:SNPHY CUSIPN/A CIK1501108 Webwww.santen.com Phone(167) 664-8621FaxN/AEmployees4,144Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E Ratio0.09 Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesMr. Takeshi Ito (Age 65)President, CEO & Representative Director Mr. Kazuo KoshijiChief Financial Officer & Chief Risk OfficerMs. Rie NakajimaCOO & Corporate OfficerMr. Minori HaraChief Digital & Information OfficerMs. Kaori ItagakiGeneral Manager of Investor Relations GroupMs. Mika MasunariGeneral Counsel & Chief Compliance OfficerMs. Nobuko KatoChief Communications OfficerMr. Satoshi Suzuki (Age 61)Senior Corporate Officer & Head of Corporate Development Division & Director Mr. Shinichi TeramachiCorporate Officer, Head of Sales Department & Japan Sales and Marketing DivisionMr. Ippei KuriharaCorporate Officer and Head of Marketing Department, Japan Business, Japan Sales & Marketing DivisionMore ExecutivesKey CompetitorsAstraZenecaOTCMKTS:AZNCFCosmo PharmaceuticalsOTC:CMOPFCSPC Pharmaceutical GroupOTCMKTS:CSPCYDaiichi SankyoOTCMKTS:DSNKYDechra PharmaceuticalsOTCMKTS:DCHPFView All Competitors SNPHY Stock Analysis - Frequently Asked Questions How have SNPHY shares performed in 2024? Santen Pharmaceutical's stock was trading at $9.85 at the beginning of 2024. Since then, SNPHY stock has decreased by 1.7% and is now trading at $9.68. View the best growth stocks for 2024 here. Are investors shorting Santen Pharmaceutical? Santen Pharmaceutical saw a drop in short interest in March. As of March 15th, there was short interest totaling 100 shares, a drop of 99.5% from the February 29th total of 20,800 shares. Based on an average trading volume of 2,200 shares, the short-interest ratio is presently 0.0 days. View Santen Pharmaceutical's Short Interest. Is Santen Pharmaceutical a good dividend stock? Santen Pharmaceutical (OTCMKTS:SNPHY) pays an annual dividend of $48.30 per share and currently has a dividend yield of 1.47%. The dividend payout ratio is 46.34%. This payout ratio is at a healthy, sustainable level, below 75%. How do I buy shares of Santen Pharmaceutical? Shares of SNPHY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:SNPHY) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarHe Is Giving Away BitcoinCrypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Presstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyThe #1 Crypto for 2024InvestorPlaceFed launches fourth dollar overhaulStansberry ResearchNew Trump BombshellThe Freeport Society Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Santen Pharmaceutical Co., Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
